With PhII suc­cess, Bridge­Bio wades deep­er in­to dwarfism drug de­bate

Bridge­Bio’s ex­per­i­men­tal drug de­signed to treat com­pli­ca­tions of achon­dropla­sia, or dwarfism, great­ly sur­passed Wall Street ex­pec­ta­tions Mon­day morn­ing in the fi­nal co­hort of a Phase II tri­al, send­ing the com­pa­ny’s stock climb­ing high.

In­fi­gra­tinib, an oral small mol­e­cule drug tar­get­ing the gene that caus­es dwarfism, in­duced rough­ly three-cen­time­ters-per-year faster growth com­pared to base­line in 10 pa­tients af­ter six months, Bridge­Bio said Mon­day. The com­pa­ny has al­ready start­ed en­rolling pa­tients for a Phase III tri­al and will take this co­hort’s dose — 0.25 mg/kg — in­to the piv­otal study, CEO Neil Ku­mar told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER